Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that on July 1, 2026, the company's holding subsidiary Jushi Biotech signed a “Cooperation, Choice and Authorization Agreement” with AstraZeneca to develop strategic cooperation with AstraZeneca in the field of novel low-interfering nucleic acid candidates to develop novel low-interfering molecular nucleic acid candidates for extra-hepatic delivery. According to the agreement, Jushi Biotech has received a down payment of 30 million US dollars from AstraZeneca on August 12, 2026 (the actual payment amount is subject to deduction of bank charges).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.